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Abstract: 
Hantavirus pulmonary syndrome (HPS) is an endemic disease in Argentina, one of the 
most affected countries in the Americas. Andes virus (ANDV) is the main 
Orthohantavirus species causing HPS in Argentina. In this work, the geographical 
distribution, clinical presentation, and epidemiological features of HPS from all 
endemic regions of Argentina were analysed. We focused on the clinical and 
epidemiological data from 533 HPS cases confirmed during the period 2009 to 2017 
by the National Reference Laboratory for Hantavirus (NRLH). A case-fatality rate of 
21.4% was registered, and most of the cases presented a severe clinical picture 
requiring intensive care treatment (84%). In order to analyse HPS case-fatality rate 
trends in Argentina since its first detection in 1995 all laboratory-confirmed case-
patients were considered, showing a general trend towards a decrease. After more 
than 22 years of experience in HPS diagnosis and surveillance, we discuss some 
possible factors implicated in this tendency. This clinical and epidemiological 
analysis gives a global perspective, being useful to detect trends and patterns, in order 


















Hantaviruses include human pathogens responsible for hemorrhagic fever with renal 
syndrome (HFRS) in Europe and Asia and hantavirus pulmonary syndrome (HPS) in 
the Americas, respectively 1,2. The first pathogenic American hantavirus was 
characterized in the southwestern United States in 1993 after an unusual outbreak of 
respiratory disease in the Four Corners region 3,4. Two years later a similar outbreak 
occurred in the Andean region of Patagonia, Argentina, leading to the characterization 
of Andes virus (ANDV) 5,6. 
Hantaviruses are tri-segmented-RNA viruses belonging to the Hantaviridae family, 
Orthohantavirus genus7, and are maintained in nature by small mammals (rodents, 
shrew, moles, bats) and their transmission occurs ex-vivo without intermediate 
vectors. These viruses establish persistent infections in several species of rodents and 
insectivores8. 
After the description of ANDV and its rodent reservoir, Oligoryzomys longicaudatus, 
several variants of this virus were confused with new orthohantaviral species because 
they were identified in different rodent species 5,9. However, further genetic analysis 
has demonstrated that the aminoacidic divergence among them was not enough to 
consider them as separate viral species10-12. It is noteworthy that ANDV is the 
causative agent of almost all HPS cases in Argentina 10,13; the only exception is 
Laguna Negra virus (LNV), which was identified in very few HPS cases in the 
Northwest region14. The variants or genotypes of ANDV are differently distributed 
among each endemic region in the country. All pathogenic genotypes of ANDV found 
in Argentina have in common that their reservoir hosts belong to the Oligoryzomys 
genus. 
 











The main mechanism for humans to become infected is by inhaling aerosolized 
excreta from reservoir hosts 15. However, ANDV is also capable of person-to-person 
transmission, a mechanism that makes it unique among hantaviruses 16-18. After an 
incubation period of up to 40 days, HPS begins with a febrile phase indistinguishable 
from other viral prodromes 19. At the end of this phase, which can last from 3 to 6 
days, dry cough and dyspnoea typically appear. This marks the beginning of the 
cardiopulmonary phase characterized by pulmonary edema due to capillary leakage, 
with a typically abrupt progress that can be followed by cardiogenic shock in few 
hours. ANDV, like other American hantaviruses, is considered one of the most lethal 
human pathogens 19-21. A major problem is that there are no vaccines or therapeutics 
approved to prevent or ameliorate this devastating disease 22. 
Although HPS was firstly described in the early 1990´s in the Americas, it is still 
considered an emerging disease due to the ongoing process of the discovery of novel 
hantaviruses, and the cyclic reemergence of certain orthohantavirus species in clusters 
or outbreaks of human infections 2. HPS emergence is thought to be driven mainly by 
socio-economic and environmental factors, such as unfavorable working conditions in 
rural areas and precarious housing, and unpredictable changes in rodent populations.  
The aim of this study was to present an extensive description of the epidemiological 
situation of HPS in Argentina, to accurately determine the region of infection of 
patients with travel records inside the country and to establish case fatality rates and 
tendencies in the period 2009-2017. 
Methods 
HPS case definition. A suspected case was defined as a patient who resides or report 
a recent travel history to an endemic region, with persistent fever (>48hs) showing 
headache, myalgias and gastrointestinal manifestations (abdominal pain, vomiting 
 











and/or diarrhea), and a marked decrease in platelet count. This definition was 
particularly applicable to find patients during the earlier phase of the disease. In an 
advanced stage, also patients with any sign of respiratory compromise. Any febrile 
person who has been in contact during the previous 35 days with a recently 
laboratory-confirmed HPS case was also considered. 
Study population. We analyzed blood samples from patients who met to the 
definition of suspected case from all the country during the period 2009-2017, which 
were received directly in the National Reference Laboratory (NRL) or through any of 
the provincial laboratories from the national laboratory network for hantavirus 
(NRLH). 
Clinical severity classification. We were able to categorize 519 case-patients by their 
clinical picture severity using the classification criteria as previously described 25. 
Briefly, Grade I for patients with prodromal symptoms without respiratory 
compromise; Grade II for patients with mild to moderate respiratory compromise 
without hemodynamic compromise; Grade III for patients with severe respiratory 
insufficiency with hemodynamic compromise; Grade IV for patients with severe 
respiratory insufficiency and refractory-to-treatment hemodynamic compromise with 
fatal outcome. 
Study design. The epidemiological study presented here was a descriptive and 
retrospective analysis. HPS cases were classified according to the ordinal variable 
severity grades and described by the following nominal variables: sex, geographical 
regions (namely: Northwest, Northeast, Central, Cuyo, and Patagonia), clinical 
symptoms, and risk activities. Finally, we analysed age as a quantitative continuous 
variable. 
 











In order to study the risk activities we defined 4 categories of exposure in a period of 
30 days before the onset of symptoms: Occupational, persons who performed 
activities related to their work; Recreational, persons who performed activities in wild 
environments or rural surrounding (camping, fishing, trekking, etc); Peridomestic, 
rural or suburban residents without defined events of exposure in other places, 
considering housing and the surrounding land the source of infectious rodents; 
Human-to-human transmission, persons who were in close contact with confirmed 
HPS case-patients 17. Patients with travel records outside the country during their 
most probable exposure or patients with travel records to endemic areas out of 
Argentina were excluded from the analysis. 
The diagnosis was performed on serum or blood samples from suspected cases 
detecting specific immunoglobulin (Ig)M by ELISA (μ-capture technique) and IgG 
against ANDV recombinant nucleoprotein (NP), which was developed and produced 
at the NRLH as previously described 23. 
Laboratory confirmation of HPS cases. Cases were laboratory-confirmed by the 
presence of both IgM and IgG antibodies; cases with IgM titres but not IgG were 
confirmed verifying IgG seroconversion in second samples and/or by viral RNA 
detection. ELISA techniques were validated using confirmed HPS sera from all 
regions of the country, in order to evaluate the specific response against all different 
circulating genotypes of ANDV and LNV. In the same way, 2 groups of samples were 
also tested for specificity: non-reactive sera for ANDV-NP and reactive sera for 
pathologies considered in the differential diagnosis for HPS (data not 
published).Diagnostic sensitivity and specificity parameters were determined by ROC 
curves for IgM and IgG, showing 96.6% and 90.6% values respectively. Viral RNA 
detection and genetic characterization were performed, when necessary, by 
 











quantitative RT-PCR (RT-qPCR) and RT-PCR followed by nucleotide sequencing 
respectively, as previously described 10,24. RT-qPCR was used to quantify the S 
segment. RT-PCR was used to amplify partial genome sequences from the S segment 
and M segment coding regions. 
Data analysis and Statistics. In order to study differences in the geographical 
distribution of cases, the Kruskal-Wallis test was performed. Case-fatality rate 
according to sex were compared by Fisher Exact test and Chi-square for trends was 
used to analyse the annual number of cases. Data was statistically analysed using 
GraphPad (Prism 6.0, GraphPadSoftware Inc. San Diego, CA). Geographic 
Information System QGIS “Las Palmas” (version 2.18.11, 
http://www.qgis.org/es/site/) was used to evaluate HPS case distribution in the 
country. 
Results 
Diagnosis and laboratory confirmation 
The NRLH received 4488 samples from HPS suspected cases during the period 2009 
– 2017, of which 533 HPS cases were laboratory confirmed (11.9% of all suspected 
samples), around 59 cases per year, on average. Since HPS is a reportable disease, 
cases were notified through the National Health Surveillance System (SIVILA). 
Although 241 additional cases were reported through SIVILA by independent 
laboratories usually performing diagnostic tests not validated by the NRLH, those 
cases were not taken into account for this study. Standardized information was 
required for each suspected cases through HPS clinical/epidemiological forms. The 
overall case-fatality rate tendency was 21.4%.In the present study, 94.2% (502/533) 
of the samples sent for diagnosis had detectable levels of both IgM and IgG specific 
antibodies against ANDV. The remaining 5.8% (31/533) were confirmed by direct 
 











viral genome detection. Some patients showed only IgG reactivity, but due to the 
absence of IgM, no seroconversion and no viral genome amplification (n=51), were 
not considered as current acute HPS cases. 
Time elapsed between onset of symptoms and sampling date was on average 5.9 days 
(median=5; n=443). For Northwest the median value was 4, n=223; Central 6, n=155; 
Patagonia 5, n=63; Northeast 6, n=2. The differences were statistically significant 
(p<0.0001, Kruskal-Wallis test). 
Temporal and Geographical distribution of Cases 
The analysis of geographical distribution of cases showed that HPS were reported in 4 
out of 5 geographical regions of the country: Northwest, Northeast, Central, and 
Patagonia, but not in Cuyo region (Table 1). Cases inside each region were restricted 
to relatively small areas as shown in Figure 1. The Northwest was the most affected, 
showing 48.7% of cases (260/533), followed by Central and Patagonia with 36.7% 
(196/533) and 14.1% (75/533) respectively. Only 2 cases occurred in the Northeast 
region, 0.4% (Table 1 and 4).Seasonal distribution was marked, the warmer seasons 
being when more cases occurred; this distribution was consequently wider in the 
tropical region of the country (Figure 2 C). We observed a highly variable annual 
distribution with different patterns according to each region (Figure 2 A). 
HPS affected all age groups, the age ranged from 0 to 86 years old (mean=32.5; 
median=31); 7.4% of cases were children (<14 years of age). The youngest case was a 
15-day-old newborn child who was probably infected by his mother, who was 
retrospectively classified as a suspected case based on clinical and epidemiological 
data after her death. Among the present case series, 78.7% were male patients (Figure 
3). 
 











The overall annual incidence ranged from 1.15 to 1.85 in the period, showing wide 
variations between regions: 9, 1 and 5 per 1000000 persons in Northwest, Central and 
Patagonia respectively. This analysis was performed on the basis of the last national 
census (www.indec.gov.ar). 
Clinical Characteristics 
Although the course of the disease was highly variable, most of the cases presented 
the typical clinical picture described for HPS. Most cases (99.4%) were hospitalized, 
excluding 3 asymptomatic cases detected due to a study of contacts and some other 
patients showing only prodromal symptoms in the Northwest region. As shown in 
Table 2, 84.2% (437/519) of cases developed a severe disease requiring intensive care 
(severity groups II, III and IV) and at least 31.4% (163/519) of those cases required 
mechanical ventilation (III and IV). The prodromal phase was short, 3 to 5 days, 
followed by different degrees of respiratory compromise, usually acute distress with 
rapid progression to respiratory failure. Besides fever, the most frequent prodromal 
symptoms were headache, myalgia, arthralgia and conjunctival injection and retro-
ocular pain. Gastrointestinal symptomatology was common and some patients showed 
abdominal pain even before any other prodromal symptoms.  
Neurological manifestations were rarely reported (6.9%), confusional syndrome being 
the most frequently observed, while some patients showed severe complications as 
convulsions and/or encephalitis (Table 3). Thrombocytopenia was present in 84% of 
cases (Range 7,000 - 511,000 cells/ml; mean value = 70271; n = 426); and petechiae 
was also common. Other hemorrhagic manifestations were rarely observed. 
Case-fatality rate 
The overall case-fatality rate was 21.4% in this period and varied significantly 
between geographical regions showing an increasing trend southwards: Northwest 
 











(15%), Central (23.9%) and Patagonia (36%) (p<0.0001 Chi-square for trends) (Table 
4). The Northeast region only reported 2 cases during this period, 1 of them being 
fatal. Although fatal outcome was higher for female, the difference by sex for the 
whole period was not significant (27.4% vs 19.9%) (p <0.0936 Fisher Exact test). The 
fatality rate of HPS per million population in the studied period was: 12 (Northwest); 
2 (Central) and 15 (Patagonia). The age-adjusted fatality rate was 12.2; 1.8 and 13.9; 
respectively (Waterhouse standard population) and results similar to the crude case-
fatality rate. 
Exposure activities 
In order to study the risk activities associated with infection and according to 
information provided by clinical/epidemiological forms we classified 441 cases in the 
following rodent exposure groups: 55.8% occupational, 14.3% recreational, 28.1% 
peridomestic; the remaining 1.8% reported contact with previous cases and probable 
person-to-person transmissions (Table 4). The regional comparison showed that 
occupational exposures were most frequent in all regions, with the highest values in 
Northwest. This kind of exposures affected mainly rural workers, although other 
activities such as security personnel and truck drivers were also reported. Exposure to 
a previous confirmed HPS case was only reported in Central and Patagonia. These 
events of exposure were accurately analysed for most of the cases from the Central 
region in a previous work26. 
The determination of the viral genotype helped to figure out the most probable site of 
infection in several patients who had a travel record history within the previous 30 
days before the onset of symptoms (Table 5). One particular case was a patient who 
died in Buenos Aires City, Central region, but with rural exposure outside the known 
 











endemic area of the Northwest region. This allowed us to confirm the first case in 
Tucuman Province 27.  
Discussion. 
In this work, we accurately analysed the epidemiological situation of more than 500 
HPS case-patients in Argentina during a 9 year period and the tendency of case-
fatality rate since its first description. This analysis represented around 70% of HPS 
reported cases in Argentina, 533 definitely confirmed HPS cases. A previous work of 
our group reported an average of 50.8 cases/year during the period 1995-2008, while 
during the present period the mean number of cases per year was 59.2, representing an 
increase of around 14% 19. We observed an expansion of the area of cases in the 
Northwest 27. Cases have been reported in 12 out of 24 Argentine provinces since 
1995. Although the most affected regions in number of cases were Northwest and 
Central regions, the highest rate of incidence per million persons was found in 
Patagonian region. Comparing these values for Argentina and the United States of 
America (USA), which ranged from 1.15 to 1.85 and 0.04 to 0.19 HPS cases/million 
persons respectively, Argentina showed at least 10-fold higher incidence rate 28. It is 
worth noting that the endemic Andean region in Patagonia is a particularly touristic 
zone where several infections led to the exportation of ANDV cases to other counties 
and/or non-endemic places in Argentina17,29,30. Furthermore, the current HPS-case 
distribution is not conclusive and it does not imply that other areas may be affected in 
the future. The presence of Oligoryzomys longicaudatus was predicted to be present 
with high probability by modelling approaches all along the Andean Mountains in 
Patagonia31. Since this predicted host distribution area is wider than the HPS endemic 
area for ANDV-South, new endemic places could be expected in the future especially 
associated with demographic increments in human population. Nevertheless, 
 











considering the ex-vivo viral transmission mechanism, virus survival is probably 
restricted to high humid environments, beyond the natural presence of the host. 
Although the interannual variation was marked, there was a slight tendency towards 
increment of cases in the period, particularly in the Central region. Conversely, the 
notable decrease in the count during the last 2 years in the Northwest region marked a 
reduction trend there. It is noteworthy that HPS case number was relatively stable in 
the Patagonia region since during the study period a particular phenomenon took 
place all along the endemic area inside the region of Patagonian Forests: the flowering 
of the Colihue cane (Chusquea culeou) 32. The overwhelming abundance of seeds is 
one of the causes for rodent population increasing. The prediction of this phenomenon 
allowed the implementation of preventive campaigns throughout the region, so its 
impact with an increase in human hantavirus infections could be avoided. The stable 
tendency in the occurrence of cases in this southern region of the country 
demonstrated the effectiveness of preventive measures to reduce rodent-human 
interaction in the area. 
It is noteworthy the importance to perform studies at a national level because they 
give a global perspective of the disease. They are also useful to detect trends and to 
evaluate the impact of the already implemented measures at regional or even at a 
national level. HPS has been associated with high case fatality rates and is considered 
one of the most lethal viral diseases 19,28,33-35. Only 2 countries performed previous 
case-series studies at a national level in The Americas spanning long periods of time: 
the USA and Argentina. In the USA during the period 1993-2009, there were reported 
30 cases per year on average (n=510) and the case fatality rate was 35%. In 
Argentina, during a shorter period of 14 years, 710 cases were reported in the period 
1995-2008 with an overall case-fatality rate of 25.8% 19,28. Adding the 533 new cases 
 











reported in the present work, a total of 1243 HPS laboratory confirmed cases were 
indentified during 22 years of surveillance in Argentina. During the present study 
period, the case-fatality rate in the entire country was 21.4%, indicating a decrease 
compared to the previous period 19. In spite of this, the clinical picture observed was 
moderate to severe, in general, requiring hospitalization in almost all patients. The 
decrease in case fatality rate could be explained by the cumulative medical experience 
in the supportive treatment for this pathology and/or the improved technology in 
respiratory assistance. It is noteworthy that the case-fatality rate was lower among 
patients treated in hospitals with previous experience in HPS treatment. Given the 
absence of preventive vaccines or specific therapeutic treatments for HPS, to turn 
case-fatality rate even lower, prompt transfer of patients to experienced and 
specialized centres in supportive treatments should be evaluated. On the other hand, 
differences in clinical picture and case-fatality rates between regions could also be 
related to unknown viral determinants among genotypes and/or differences in human 
population susceptibilities. To figure out its definite origin particular studies should be 
focused on both these aspects in the future. 
Due to the variable and long incubation period of HPS, in which some cases reported 
multiple risk activities, to assess accurately the source of infection was very difficult. 
Analyzing the information related to the source of exposure, we identified that 
occupational activities were most frequently associated with HPS in each region and 
were mostly related to rural activities. This would indicate the need of preventive 
approaches, policies and/or employee education programs. Population with potential 
for frequent rodent exposure should be aware of the risks for hantavirus infection at 
their workplaces. On the other hand, exposures to previously confirmed cases were 
mostly reported in Patagonia (8%), but few cases also occurred in the Central region 
 











(2%), where ANDV- South and ANDV- BsAs genotypes were associated to well 
defined person-to-person transmission respectively 17,26. Larger educational efforts 
should be carried on in order to reduce exposure risk in all categories. 
Given the extensive territory of the country, our main limitation for a more accurate 
HPS surveillance was the non-standardized data obtained from each province. 
Misdiagnosis or incomplete diagnosis of HPS cases in Argentina was also an 
important limitation for our present analysis because independent laboratories 
reported around 30% of the suspected cases without the supervision of the NRLH, and 
could not be included in this analysis. The reinforcement of the Hantavirus National 
Laboratory Network, lead by the NRLH, adding new nodes that could perform a local 
(at the Provincial level) and early diagnosis with validated techniques will help to 
decrease misdiagnosis, to improve detection and, therefore, to improve survival of 
patients. This might be also useful to decrease underreporting in Argentina. A 
multidisciplinary public health effort will be required to improve surveillance, 
decrease underreporting of HPS, and carry out extensive reservoir studies all around 
the country to determine a complete risk map at a national level. This will help to 
design and conduct epidemiological studies and preventive measures at a national 
level. 
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Figure 1. Geographical distribution of HPS cases in departments in Argentina, 2009-















Figure 2. Temporal HPS case distribution in Argentina, 2009-2017. A) Annual 
distribution by geographical regions, n = 533. B) Annual distribution (bars) and case-
fatality rate (red line), n = 533. C) Case distribution by month and geographical 















Figure 3. HPS case distribution by sex and age groups and case fatality rate in 
Argentina, 2009-2017 (n = 517). White bars and black lines show male patients, red 
bars and red lines female patients. 
 
Tables. 
Table 1: HPS case patient distribution by geographic regions, Argentina, 
2009-2017. 
Geographic Region Provinces that reported HPS cases * Hantavirus variants circulating in the 
region† 
Number of cases in 
the present period 
Northwest Salta, Jujuy, Tucumán Andes-Oran, Andes-Bermejo, 
Laguna Negra virus 
260 
Northeast Corrientes, Formosa Andes-Lechiguanas; Andes 
Juquitiba 
2 
Central Buenos Aires, Buenos Aires city, 




Patagonia Neuquén, Rio Negro, Chubut Andes-South 75 
 
* Only provinces with >1 probable rodent exposure. 
† Data provided by previously published studies, period 1995-2017.  
 
 











Table 2. Clinical classification of HPS cases by severity, Argentina, 2009-
2017. 
 
No. case-patients (%) 
Severity Group Northwest Central Patagonia Total 
0 3 (1.2) 0 0 3 (0.6) 
I 62 (24.2) 12 (6.3) 3 (4) 77 (14.8) 
II - 78 (41.3) 27 (36.5) 165 (31.8) 
III - 37 (19.5) 15 (20.3) 57 (11) 
II / III * 152 (59.4) 15 (8) 2 (2.7) 104 (20) 
IV 39 (15.2) 47 (24.9) 27 (36.5) 113 (21.8) 
n = 519 (Northwest= 256; Central: 189; Patagonia: 74) 
*Clinical/Epidemiological form used in the Northwest region did not provide the information required to classify 
casesamong Grade II or III.  
Table 3. Clinical symptoms reported in confirmed HPS cases, Argentina, 
2009-2017. 
 
Clinical symptoms and findings 
No. case-patients (%) 
Northwest Central Patagonia Total 
Respiratory and circulatory (Cough, 
Dyspnoea, Tachypnoea, Shock) 176 (68.6) 177 (89.4) 61 (89.7) 414 (79) 
Hepatic (hepatomegaly, elevated GOT, 
GPT, and LDH) 21 (8.2) 83 (41.5) 25 (36.75) 129 (24.6) 
Renal (elevated levels of creatinine, 
oligoanuria, renal failure) 25 (9.8) 45 (22.5) 22 (32.34) 92 (17.6) 
Hemorrhagic manifestations (Conjunctival 
injection, Petechiae, Purpura, 
Hemoptysis, Melena, Epistaxis, etc.) 
42 (16.4) 39 (19.5) 6 (8.8) 87 (19.6) 
 











Gastrointestinal (Abdominal pain, 
Vomiting, Diarrhoea) 152 (59.3) 59 (29.5) 12 (17.6) 223 (42.5) 
Neurological (Confusional syndrome, 
Seizures, Encephalitis, Meningitis, 
Photophobia) 
11 (4.3) 19 (9.5) 6 (8.82) 36 (6.9) 
Retro-ocular pain 96 (37.4) 19 (9.5) 0 (0) 115 (21.9) 
n = 524 (Northwest= 258; Central: 198; Patagonia: 68). 




Case-fatality rates (%) 
 
Characteristic 
Northwest Central Patagonia Northeast Total 
M † 13.5 22.1 35.7 50 19.8 
F † 20.8 31 36.8 - 27.2 
Total 15 * 23.9 * 36 * 50 21.4 
Type of Exposure 
N° of case-patients (%) 
 
Occupational 147 (64.2) 72 (48.7) 27 (42.2) - 246 (55.8) 
Recreational 32 (14) 21 (14.2) 10 (15.7) - 63 (14.3) 
Peridomestic 50 (21.8) 52 (35.1) 22 (34.3) - 124 (28.1) 
Contact with previous HPS 
case-patient 
0 3 (2) 5 (7.8) - 8 (1.8) 
 
Nº of HPS cases per geographic region (n=533).Type of exposure was classified according to most probable risk 
activities during the estimated incubation period. (n=441). * The fatality rates varied significantly between regions 
(p<0.0001 Chi-square for trends). † Not significant difference was observed in fatality rate associated to sex (p 
<0.0936 Fisher Exact test). 
 
 















Residence place Probable site of infection 
Genotype 
G. Region City/Province G. Region Province 
F41 jan-10 Central CABA Patagonia Bariloche/RN ANDV-South 
F46 mar-10 Central CABA Central Pilar-Tandil/BA; Gualeguaychú/ER ANDV-BsAs 
F24 feb-12 Central San Martin/ER Patagonia Bariloche/RN ANDV-South 
M42 jan-13 Central CABA Central Tigre /BA ANDV-Lech 
M28 apr-13 Central CABA Patagonia Bariloche/RN ANDV-South 
M2 apr-14 Central CABA Patagonia Dina Huapi/RN ANDV-South 
F56 jan-14 Cuyo Merlo/ SL Central Castelli /BA ANDV-BsAs 
F26 jan-14 Central CABA Patagonia RN, CH ANDV-South 
F36 jan-17 Cuyo Mendoza/ME Central Monte Hermoso, BA ANDV-BsAs 










M18 feb-17 Central CABA Patagonia Bariloche/RN ANDV-South 
 
BA: Buenos Aires; CABA: Ciudad Autónoma de Buenos Aires; ER: Entre Rios; RN: Rio Negro; CH: Chubut; SL: San 
Luis; SMA: San Martín de los Andes; TU:Tucuman; LGSM: Libertador General San Martin; ME: Mendoza; Santa Fe; 
NQ: Neuquen. 
 
